The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | COVID-19-related risk factors in patients with blood cancers
Lisa Hicks, MD, MSc, St. Michael’s Hospital, Toronto, Canada, provides an overview of risk factors associated with hospitalization and mortality from COVID-19 in patients with hematologic malignancies. 1029 patients with a malignant diagnosis from the ASH Research Collaborative (RC) COVID-19 Registry for Hematology were included in the analysis and patients who were male, over 60 years of age, had a pre-COVID-19 prognosis of less than 6 months, and an ICR deferral were found to have an increased mortality risk from COVID-19. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
